Elubrixin

Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM) . Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation[1][2][3].

Product Specifications

CAS Number

[688763-64-6]

Product Name Alternative

SB-656933

UNSPSC

12352005

Hazard Statement

H361-H373

Target

CXCR; Interleukin Related

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/elubrixin.html

Solubility

10 mM in DMSO

Smiles

O=C(NC1=CC=C(Cl)C(S(=O)(N2CCNCC2)=O)=C1O)NC3=CC=CC(F)=C3Cl

Molecular Formula

C17H17Cl2FN4O4S

Molecular Weight

463.31

Precautions

P260-P280-P405-P501

References & Citations

[1]Mozaffari S, et al. Inflammatory bowel disease therapies discontinued between 2009 and 2014. Expert Opin Investig Drugs. 2015;24 (7) :949-56.|[2]Lazaar AL, et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol. 2011 Aug;72 (2) :282-93.|[3]Nicholson GC, et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther. 2007;20 (1) :52-9.